Brassicasterol, as a metabolite of ergosterol, exhibits cardiovascular protective properties. This compound demonstrates antitumor effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol shows inhibitory activity against HSV-1 (IC50=1.2 µM) and Mycobacterium tuberculosis. By inhibiting sterol delta24-reductase, it delays atherosclerosis progression and has been identified as a cerebrospinal fluid biomarker for Alzheimers disease.
